arrow
E

E. Gary

the wistar institute
H指数:18
被引数:3,087

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins

单剂量质粒DNA的工程设计以实现体内长效递送定制型肠促胰岛素

2026-06-190
OA
Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization

靶向RBD的纳米颗粒诱导交叉反应性、RBD靶向的应答,能够抵抗变异株的SARS-CoV-2中和

2026-02-200
PRE
Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination
2026-01-280
OAAI
Synthetic DNA co-immunization with vaccine-aligned common consensus nucleoprotein and hemagglutinin protects mice against lethal influenza infection with a single immunization

合成DNA与与疫苗同源的通用共同核蛋白和血凝素共免疫,单次免疫即可保护小鼠免受致死性流感感染

2025-11-260
OAAI
Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenza

电穿孔和LNP介导的质粒DNA编码的H5N1流感病毒血凝素递送支持对高致病性禽流感的保护

2025-11-220
OAAI
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo

DNA共递送季节性H1流感血凝素纳米粒疫苗与趋化因子佐剂CTACK可诱导体内强大的异源保护性免疫原性。

VACCINE
IF3.5
2025-06-010
PRE
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

低剂量或单剂量疫苗应用优化的自复制RNA平台的安全性与免疫原性:一项在健康志愿者中进行的随机、开放标签I期研究

2025-01-074
OA
In vivo delivery of engineered synthetic DNA-encoded SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis in non-human primates
2024-02-280
OAAI
Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge
2023-03-144
OAAI
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2
2022-10-0618
OAAI